Objective
Lung cancer has the highest incidence and mortality rates of all cancers, and patient survival is strongly linked to early detection. Therefore, low-dose CT screening of high-risk individuals, the only method proven to improve survival, is now recommended by major health organisations. There are, however, concerns with the high rate of false positives and increased radiation exposure associated with screening. We propose to investigate the clinical benefits of spectral CT for lung nodule detection and characterisation. The unique, photon-counting, spectral silicon detector developed by the host group offer twice the resolution, no lower dose limit, reduced artefacts, and higher contrast sensitivity than current state-of-the-art. Our hypothesis is that the patient dose can be significantly reduced in both the detection and characterisation steps, and that the higher resolution will reduce false positives. The reduction in screening dose alone would prevent an estimated 15 cases of induced cancer per 10,000 individuals screened. Fewer false positives would then further reduce the dose through fewer follow-ups and characterisations, lower clinical costs and workload, and reduce patient distress. The fellowship would allow the researcher to benefit from the world-class research, close ties to commercial partners and strong international collaborations of the host, and the exceptional clinical expertise of the partner organisation. In particular, training in cutting-edge detector technology, novel image reconstruction techniques and management of patient studies would complement the researcher’s strong background in medical physics and image analysis. The training, expected high-impact research and networking opportunities will strongly enhance the career prospects of the researcher, the outreach activities will give public awareness of the potential of spectral CT, and the expected clinical gain will benefit society at large, in particular future lung cancer patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology lung cancer
- engineering and technology medical engineering diagnostic imaging computed tomography
- medical and health sciences clinical medicine radiology
- natural sciences computer and information sciences artificial intelligence machine learning deep learning
- natural sciences chemical sciences inorganic chemistry metalloids
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
100 44 Stockholm
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.